Study of AT-587 in Healthy Subjects
← catalyst calendarNCT07728487 · readout ≤ 134 d
Sponsored by Atea Pharmaceuticals, Inc. (industry) · AVIR — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
62estimated
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-13 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatitis E
Interventions
- Drug: AT-587
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFProportions (active vs. Placebo) of subjects experiencing treatment-emergent adverse events
measured Day 1 up to Day 13
Permalink · AVIR's whole pipeline · Catalyst calendar · Every registered study · What changed